Research and Markets - Commercial Viability of Phosphatase Enzyme Class as Therapeutic Targets Analysed

Research and Markets (researchandmarkets.com/reports/c9232) has announced the addition of Phosphatases: Emerging Role in Signal Transduction, Human Therapeutics, & As Drug Targets to their offering.

(PRWEB) November 15, 2004 -- Research and Markets (http://www.researchandmarkets.com/reports/c9232) has announced the addition of Phosphatases: Emerging Role in Signal Transduction, Human Therapeutics, & As Drug Targets to their offering.

Recently, several members of the phosphatase drug target class have been identified and classes of compounds have been screened with hits identified. This activity has prompted several pharmaceutical companies to devote a portion of their pipelines to the development of this promising class. In particular, a multi-million dollar commitment has been made by companies towards the development of phosphatases shown to be associated with obesity and cancer.

This comprehensive analysis covers the commercial viability of the phosphatase enzyme class as therapeutic targets. It provides an in-depth analysis of the emerging market for phosphatases. What phosphatases are is clearly defined, including their classification, role in diseases, role in signal transduction, and as potential targets for developing therapeutics. The intellectual property landscape is reviewed, companies invested in phosphatase development are profiled, and key industry players are interviewed.

This report will enable readers:
-Pinpoint the full potential of the phosphatases drug target class with an examination of the projected impact across several markets.
- Determine the advantage of phosphatases for developing human therapeutics over other known classes of drug targets through a comprehensive breakdown of their classifications, mechanisms, and limitations.
- Discover the commercial viability of phosphatases through a detailed analysis of their role in signal transduction and as targets for human therapeutics.
- Learn about the current intellectual property landscape via an in-depth review of patents covering phosphatases and their inhibitors.
- Gain reliable and thought-provoking insights into the phosphatases market through interviews with authorities involved in this industry.
- Look inside companies working within the phosphatases field, including their product pipelines, partnerships & alliances, business strategies, technologies, and more.

Companies profiled in this report include:
- Ceptyr
- ISIS Pharmaceuticals
- Serono PRI
- Sunesis
- Vertex

Chapters Provided Include:
-Introduction and Background
-Phosphatases in Signal Transduction
- Phosphatases Associated with Disease
- Commercial Opportunity and Legal Aspects of Commercialization
-Structural Challenges in Developing Anti-PTP Molecules
- Literature and Latest News on Phosphatases
- Intellectual Property Landscape for Phosphatases and Their Inhibitors
- Companies Providing Reagents and Assays for the Phosphatase Space
- Interviews with Industry Experts
Dr. Rob Hooft, Principal Scientist, Serono
Paul G. Abrams, M.D., J.D., Ceptyr
James Wells, Ph.D., President, Sunesis
Christopher Lipinski, Ph.D., Roche
- Company Profiles
- Ceptyr
- ISI Pharmaceuticals
- Serono Pharmaceuticals
- Sunesis
- Vertex Pharmaceutical

For more information visit http://www.researchandmarkets.com/reports/c9232

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###